vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and Q32 Bio Inc. (QTTB). Click either name above to swap in a different company.
Q32 Bio Inc. is the larger business by last-quarter revenue ($1.9M vs $1.0M, roughly 1.9× AVAX ONE TECHNOLOGY LTD.). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -1633.6%, a 4624.7% gap on every dollar of revenue.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
AVX vs QTTB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.9M |
| Net Profit | $-16.6M | $57.7M |
| Gross Margin | — | — |
| Operating Margin | -1522.1% | — |
| Net Margin | -1633.6% | 2991.2% |
| Revenue YoY | — | — |
| Net Profit YoY | -480.2% | 506.9% |
| EPS (diluted) | $32.17 | $4.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.9M | ||
| Q3 25 | $525.9K | $-220.0K | ||
| Q2 25 | $452.0K | $-284.0K | ||
| Q1 25 | $344.4K | $-371.0K | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | $41.3K | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-16.6M | $57.7M | ||
| Q3 25 | $-8.4M | $-7.4M | ||
| Q2 25 | $-8.1M | $-9.5M | ||
| Q1 25 | $-145.5K | $-11.0M | ||
| Q4 24 | — | $-14.2M | ||
| Q3 24 | $-5.8M | $-17.6M | ||
| Q2 24 | $-4.2M | $-17.0M | ||
| Q1 24 | — | $1.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1522.1% | — | ||
| Q3 25 | -496.6% | 3444.1% | ||
| Q2 25 | -328.4% | 3229.2% | ||
| Q1 25 | -600.0% | 3296.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2827.7% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1633.6% | 2991.2% | ||
| Q3 25 | -1588.0% | 3358.6% | ||
| Q2 25 | -1783.4% | 3341.2% | ||
| Q1 25 | -42.2% | 2973.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -10243.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | $32.17 | $4.70 | ||
| Q3 25 | $-5.55 | $-0.60 | ||
| Q2 25 | $-27.60 | $-0.78 | ||
| Q1 25 | $-1.17 | $-0.90 | ||
| Q4 24 | — | $2.63 | ||
| Q3 24 | $-57.19 | $-1.46 | ||
| Q2 24 | $-83.03 | $-1.42 | ||
| Q1 24 | — | $-6.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $48.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $42.0M |
| Total Assets | $195.0M | $61.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $48.3M | ||
| Q3 25 | $894.7K | $49.0M | ||
| Q2 25 | $185.3K | $54.8M | ||
| Q1 25 | $1.4M | $65.5M | ||
| Q4 24 | — | $78.0M | ||
| Q3 24 | — | $89.1M | ||
| Q2 24 | — | $97.7M | ||
| Q1 24 | — | $115.5M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $42.0M | ||
| Q3 25 | $12.2M | $-18.4M | ||
| Q2 25 | $4.1M | $-12.2M | ||
| Q1 25 | $6.4M | $-4.0M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | $6.7M | $18.3M | ||
| Q2 24 | $11.3M | $33.5M | ||
| Q1 24 | — | $48.8M |
| Q4 25 | $195.0M | $61.8M | ||
| Q3 25 | $16.5M | $57.8M | ||
| Q2 25 | $15.2M | $66.1M | ||
| Q1 25 | $16.8M | $79.1M | ||
| Q4 24 | — | $92.3M | ||
| Q3 24 | $10.8M | $104.5M | ||
| Q2 24 | $15.7M | $124.2M | ||
| Q1 24 | — | $152.3M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-6.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.11× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-6.2M | ||
| Q3 25 | $-2.4M | $-4.2M | ||
| Q2 25 | $-884.1K | $-10.7M | ||
| Q1 25 | $-2.2M | $-12.5M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | $-1.2M | $-19.5M | ||
| Q2 24 | $-919.2K | $-22.2M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $-19.6M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
